Orinox (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is an alpha‑adrenergic agonist. By stimulating α1‑receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which reduces mucosal edema and decreases resistance in the nasal airway. This mechanism leads to quick alleviation of congestion.

The exact dosing regimen for Orinox is determined by the prescribing healthcare professional. Typically, one spray per nostril is administered, not exceeding the recommended maximum duration of three consecutive days, but the prescriber will set the precise dose based on the patient’s age and clinical situation.

Safety data for xylometazoline in pregnancy and lactation are limited. Women who are pregnant, planning a pregnancy, or breastfeeding should discuss the potential risks and benefits with their healthcare provider before using Orinox.

To order Orinox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Orinox (xylometazoline) and other imidazoline decongestants such as oxymetazoline share a similar mechanism of α‑adrenergic vasoconstriction. Xylometazoline typically has a rapid onset and a duration of action of about 6‑8 hours. Compared with oxymetazoline, it may have a slightly lower incidence of rebound congestion when used within the recommended three‑day limit.

Store Orinox below 25 °C in its original container, protecting it from moisture and direct sunlight. Do not freeze the product. Keep the spray bottle tightly closed when not in use and keep it out of reach of children.

Orinox is administered as a nasal spray. The user gently inserts the tip into one nostril, depresses the pump to deliver a spray, and repeats in the other nostril if required. The recommended frequency is usually one spray per nostril, not exceeding the maximum duration advised by a healthcare professional.

The most serious risks include rebound nasal congestion (rhinitis medicamentosa) after prolonged use, significant elevation of blood pressure, tachycardia, and rare severe allergic reactions such as anaphylaxis. Patients should discontinue use and seek medical attention if they experience persistent hypertension, rapid heartbeat, or signs of an allergic response.

Orinox should be avoided in individuals with known hypersensitivity to xylometazoline or any formulation components, in children under 2 years of age unless directed by a physician, and in patients with uncontrolled hypertension, severe cardiovascular disease, or recent nasal surgery without medical guidance.